Objective: A generic cisplatin formulation has replaced the brand-name formulation since November 2003 in our hospital. We retrospectively assessed the renal toxicity caused by the brand-name and generic cisplatin formulations. Methods: The medical records of patients with thoracic malignancy who were treated at our hospital between November 2000 and April 2008 were reviewed. In total, 1296 eligible patients received 80 mg/m 2 of cisplatin: 499 patients were treated with the brand-name cisplatin formulation before November 2003 (Group 1) and 797 patients were treated with the generic formulation after November 2003 (Group 2). We compared the maximum serum creatinine level after chemotherapy in the two groups. Results: The patient characteristics, including age, sex and performance status, and pretreatment serum creatinine levels were well balanced between the two groups. More patients received four cycles of chemotherapy in Group 2 (P , 0.0001). The median (range) of the maximum serum creatinine levels during all the chemotherapy cycles were 1.1 (0.5 -4.1) mg/dl and 1.1 (0.5-4.4) mg/dl in Groups 1 and 2, respectively (P ¼ 0.0237). The incidence of grade 0 serum creatinine elevations decreased from 47% to 39%, while that of grade 1 serum creatinine elevations increased from 32% to 41% (P ¼ 0.0094). The incidence rates of grade 2 or 3 serum creatinine elevations were similar (21 vs. 20%). The time to serum creatinine elevation was also similar in Groups 1 and 2 (P ¼ 0.161). Conclusion: Although grade 1 maximum serum creatinine level was more common in the generic cisplatin formulation group, this was attributed to the larger number of patients receiving four cycles of chemotherapy in this group.
INTRODUCTION
Cisplatin-based chemotherapy is curative for testicular cancer and is active against gynecologic, gastrointestinal, genitourinary, head and neck, and lung cancers as well as other malignant diseases. Carboplatin has the same range of clinical activity as cisplatin but is less nephrotoxic and less emetogenic. Therefore, carboplatin has essentially replaced cisplatin for the treatment of ovarian cancer, lung cancer and a range of other malignancies (1) . In some diseases, such as germ cell tumors (2) , head and neck cancer (3) , and non-small-cell lung cancer (4, 5) , however, cisplatin is more effective clinically in terms of the response rate and survival.
Cisplatin can cause dose-dependent renal toxicity. Large infusion amounts are needed to prevent cisplatin-induced renal toxicity. Patients are usually prehydrated and posthydrated with at least 2 l of IV fluid to maintain good urine flow. Risk factors for cisplatin nephrotoxicity include the dose and frequency of administration and the cumulative dose of cisplatin, older age, female sex, smoking and hypoalbuminemia (6) .
Generic drugs are believed to be bioequivalent to brand-name drugs in terms of dosage form, safety, quality, performance and intended use. They are usually sold at substantial discounts from the branded price. The spread of generic drugs relieves the financial burden of patients' and improves the financial affairs of medical insurance providers (7) . Recently, a retrospective analysis from the National Cancer Center Hospital (NCCH) in Tokyo, Japan, demonstrated that renal toxicity was more severe in patients treated with a generic cisplatin formulation than in those treated with the brand-name formulation, especially among male patients (8) . To validate these findings, we conducted the same analysis in another patient cohort from the NCCH East, since the same generic cisplatin formulation had been introduced at our hospital, replacing the brand-name formulation, in November 2003.
PATIENTS AND METHODS
Patients were retrospectively selected for this study according to the following criteria, which were identical to those used in the previous analysis (8) : (i) a histological or cytological diagnosis of thoracic malignancy; (ii) no prior chemotherapy; (iii) chemotherapy with a regimen that included 80 mg/m 2 of cisplatin; and (iv) receiving treatment as an inpatient at the NCCH East between November 2000 and April 2008. During this period the brand-name cisplatin formulation was administered between November 2000 and October 2003, and CISPLATIN for I.V. infusion (MARUKO), a generic cisplatin formulation, was administered thereafter. Patients with an abnormally elevated serum creatinine (CRN) level prior to the initiation of chemotherapy were excluded from this study. Serum CRN was measured using an enzymatic assay throughout the study period. The upper limit of normal for serum CRN was 1.1 mg/dl for men and 0.9 mg/dl for women.
After 750 ml of intravenous infusion fluids, cisplatin (80 mg/m 2 ) and 300 ml of fluids were intravenously infused over a 60-min period on day 1 in combination with other chemotherapeutic agents, followed by 40 g of mannitol and 1450 ml of hydration. A total of 2500 ml of hydration fluids, which consisted of 1000 ml of normal saline and 1500 ml of hypotonic crystalloid solution (Solita-T3 w ), were infused at a rate of 300 ml/h. Twenty milligrams of furosemide was intravenously administered at the end of hydration. One thousand milliliters of intravenous infusion fluids were administered on days 2 and 3 and 500 ml was administered on days 4 and 5 at a rate of 300 ml/h. Antiemetic prophylaxis consisted of a 5HT3 antagonist and 16 mg of dexamethasone on day 1, followed by 8 mg of dexamethasone on days 2 and 3 and 4 mg on days 4 and 5. This sequence of administration was consistently maintained during the study period.
The patients' baseline characteristics including age, sex, performance status (PS), pretreatment CRN level (CRN pre ), chemotherapy regimen, number of chemotherapy cycles and maximum CRN level (CRN max ) during the first cycle and during all chemotherapy cycles were retrospectively obtained from the patients' medical records. The median CRN max and the Common Toxicity Criteria-Adverse Event (CTC-AE version 3.0) grades of the CRN max were compared in patients treated with the brand-name cisplatin formulation (Group 1) and those treated with the generic formulation (Group 2). The time to serum CRN elevation was defined as the interval between the start of chemotherapy and the development of serum CRN elevation grade 1 or worse. Patients who did not develop serum CRN elevation grade 1 or worse were censored at the end of the cisplatin-based chemotherapy. The time to serum CRN elevation was estimated using the Kaplan-Meier analysis method (9) and was compared between groups using a log-rank test. Mann -Whitney tests were used to evaluate continuous variables and x 2 tests were used for categorical variables. Multivariate analyses were performed using Cox proportional hazards models to determine the risk factors for the time until serum CRN elevation. Group 1 or 2 and the presence of significant risk factors in the univariate analyses were evaluated using a multivariate analysis. All the reported P values were two-sided. GraphPad InStat version 3.10 for Windows (GraphPad Software, San Diego, USA) and PASW Statistics 18 for Windows (SPSS Inc., Chicago, USA) were used for the statistical analyses. The present study was approved by an institutional review board.
RESULTS
Out of 1341 patients assessed for eligibility in this study, 1310 patients met the inclusion criteria; 31 patients were subsequently excluded because of an abnormal CRN pre level. An additional 14 patients were excluded because they were treated with the brand-name cisplatin formulation during the first cycle of chemotherapy but received the generic formulation in subsequent cycles. Therefore, a total of 1296 patients were eligible for this analysis. In total, 499 patients were treated with the brand-name cisplatin formulation (Group 1) and 797 patients were treated with the generic formulation (Group 2) (Fig. 1) . The patient characteristics are shown in Table 1 . The median age was 63 years (range 27 -81 years), and the female patients accounted for 23% of all the patients. No statistical differences in sex, age, PS or CRN pre were observed between the two groups. The most common chemotherapy regimen was cisplatin plus vinorelbine; however, this regimen was less frequently used in Group 2, whereas cisplatin plus gemcitabine was more frequently used. The median number of chemotherapy cycles was three in both groups, but more patients received four cycles of chemotherapy in Group 2 (Fig. 2) .
The median (range) CRN max levels during the first cycle of chemotherapy were 1.0 (0.5 -4.1) mg/dl and 1.0 (0.6 -4.2) mg/dl in the male patients in Groups 1 and 2, respectively (P ¼ 0.0378), whereas they were 0.7 (0.5 -1.8) mg/dl and 0.7 (0.4 -1.9) mg/dl in the female patients in Groups 1 and 2, respectively (P ¼ 0.3949). The CTC-AE grade for CRN max during the first cycle was not statistically different between Groups 1 and 2 in both male (P ¼ 0.6732) and female patients (P ¼ 0.9518) ( Table 2) .
The median (range) CRN max levels during all the chemotherapy cycles were 1.1 (0.5 -4.1) mg/dl and 1.1 (0.5 -4.4) mg/dl in all the patients in Groups 1 and 2, respectively (P ¼ 0.0237). The median (range) CRN max levels during all the cycles of chemotherapy were 1.2 (0.5 -4.1) mg/dl and 1.2 (0.6 -4.4) mg/dl in the male patients in Groups 1 and 2, respectively (P ¼ 0.0029), whereas they were 0.8 (0.5 -2.6) mg/dl and 0.9 (0.5 -2.2) mg/dl in the female patients in Groups 1 and 2, respectively (P ¼ 0.3745). The CTC-AE grade for CRN max during all the cycles was statistically different between Groups 1 and 2 in the male patients (P ¼ 0.0431). Grade 0 CRN max decreased from 49% to 42%, whereas grade 1 CRN max increased from 32% to 41% between the male patients in Groups 1 and 2. An identical tendency was observed in the female patients. Grade 0 CRN max decreased from 39% to 31%, whereas grade 1 CRN max increased from 31% to 41% between the female patients in Groups 1 and 2 (P ¼ 0.1455). In all the patients, grade 0 CRN max decreased from 47% to 39% and grade 1 CRN max increased from 32% to 41% between Groups 1 and 2 (P ¼ 0.0094). Grade 2 or 3 CRN max was not different between Groups 1 and 2 in both the male and female patients ( Table 3 ). The time to serum CRN elevation was not statistically different between Groups 1 and 2 (P ¼ 0.161) (Fig. 3) . A male sex or an age of 71 years or older was significantly associated with a shorter time to a serum CRN elevation grade 1 or worse in a univariate analysis (Table 4) .
A multivariate analysis showed that a female sex [hazard ratio (HR): 1.528, 95% confidence interval (CI): 1.296 -1.803] and an age of 71 years or older (HR: 1.362, 95% CI: 1.127 -1.645) were significant risk factors for the time to serum CRN elevation. Group 2 was not a significant risk 
DISCUSSION
A previous retrospective analysis from the NCCH in Tokyo, Japan, demonstrated that a grade 2 or 3 CRN max was observed in 9.4% of the male patients treated with the brandname cisplatin formulation and 20.9% of the male patients treated with a generic formulation identical to that used in our study during all the chemotherapy cycles (P , 0.001) (8) . In our study, grade 2 or 3 CRN max was observed in 19 and 17% of the male patients of the two groups, respectively. Three thousand milliliters on day 1 and 2000 ml of intravenous infusion fluids on days 2 -5 were administered at the NCCH, with identical antiemetic prophylaxis of a 5HT3 antagonist and dexamethasone and 40 g of mannitol on day 1. However, 2,500 ml of intravenous infusion fluids on day 1, 1000 ml on days 2 and 3, and 500 ml on days 4 and 5 were administered in our hospital. The median age of patients was 60 years in the NCCH study and 63 years in this study. The reason why our study could not confirm a high frequency of grade 2 -3 CRN max in the generic cisplatin formulation group is unknown. Although grade 1 CRN max was more common in the generic cisplatin formulation group, this was attributed to the larger number of patients receiving four cycles of chemotherapy in this group. A multivariate analysis also demonstrated that the generic cisplatin formulation group was not a statistically significant risk factor associated with the time to serum CRN elevation. We concluded that the generic cisplatin formulation did not increase renal toxicity compared with the brand-name cisplatin formulation.
The main objective of using generic drugs, rather than the brand-name drugs, is cost savings (10) . Generic drugs are usually approved without clinical trials, although the same high quality, strength, purity and stability as brand-name drugs are required. Our study suggested that the generic cisplatin formulation did not increase renal toxicity, compared with the brand-name formulation. This kind of survey is needed for other generic drugs, especially anticancer drugs that can cause severe or life-threatening toxicities. We believe it is important to confirm the safety of generic drugs. If possible, it is desirable to conduct clinical trials to evaluate the safety and efficacy of generic drugs before approval. However, a large-scale clinical trial needs great cost and is impracticable to conduct.
Magnesium was not included in the hydration fluid. Several randomized trials have demonstrated that the addition of magnesium is effective for reducing cisplatin-induced renal toxicity (11, 12) . Grade 2 -3 CRN max was observed in 20% of patients, which sounds still high. A four-arm cooperative study in Japan demonstrated that the incidence of grade 2 -3 serum CRN elevation was 7-9% in the cisplatin-based chemotherapy group (13) . We analyzed consecutive patients who were treated with cisplatin-based chemotherapy; therefore, more patients who had co-morbidity and were ineligible for clinical trials might have been included in this study, resulting in a higher incidence of grade 2-3 serum CRN elevation than those in clinical trials. To reduce cisplatin-induced renal toxicity, we have added magnesium to the hydration fluid administered prior to cisplatin since 2010. We plan to analyze whether preloading with magnesium before chemotherapy can further reduce cisplatin-induced renal toxicity.
Our retrospective analysis has several limitations. First, other risk factors for cisplatin nephrotoxicity, such as smoking status, pretreatment serum albumin level or the co-administration of non-steroidal anti-inflammatory agents, were not investigated. Secondly, aprepitant, which is a standard antiemetic agent nowadays (14) , was approved in late 2009 in Japan. None of the patients in our study received aprepitant. The introduction of aprepitant might reduce anorexia induced by cisplatin and might prevent dehydration and renal dysfunction. Thirdly, the frequency of chemotherapy delay, dose reduction or termination of chemotherapy due to renal toxicity was not investigated. This information will be helpful to understand the clinical impact of the renal toxicity.
In conclusion, the incidence of grade 2 -3 CRN max was not higher in the generic cisplatin group, although the incidence of grade 1 CRN max was higher. However, more patients in the generic cisplatin formulation group received four cycles of chemotherapy than in the brand-name cisplatin group. The time to serum CRN elevation was not statistically different between the two groups. Patients in Group 1 were treated with the brand-name cisplatin formulation, whereas patients in Group 2 were treated with a generic cisplatin formulation. 
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